Eli Lilly Shares Surge on Raised Sales Forecast

Eli Lilly & Co. raised its full-year sales forecast as demand for its blockbuster obesity and diabetes drugs continues to surge, sending shares higher. The update also has implications for rival Novo Nordisk, which competes in the same high-growth market. Analysts are watching how the competitive landscape evolves.